GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chongqing Lummy Pharmaceutical (SZSE:300006) » Definitions » Cyclically Adjusted Revenue per Share

Chongqing Lummy Pharmaceutical (SZSE:300006) Cyclically Adjusted Revenue per Share : ¥1.55 (As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Chongqing Lummy Pharmaceutical Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Chongqing Lummy Pharmaceutical's adjusted revenue per share for the three months ended in Mar. 2024 was ¥0.170. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥1.55 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Chongqing Lummy Pharmaceutical's average Cyclically Adjusted Revenue Growth Rate was -2.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Chongqing Lummy Pharmaceutical was 11.80% per year. The lowest was 3.80% per year. And the median was 9.20% per year.

As of today (2024-06-12), Chongqing Lummy Pharmaceutical's current stock price is ¥2.50. Chongqing Lummy Pharmaceutical's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ¥1.55. Chongqing Lummy Pharmaceutical's Cyclically Adjusted PS Ratio of today is 1.61.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Chongqing Lummy Pharmaceutical was 7.22. The lowest was 1.54. And the median was 3.54.


Chongqing Lummy Pharmaceutical Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Chongqing Lummy Pharmaceutical's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chongqing Lummy Pharmaceutical Cyclically Adjusted Revenue per Share Chart

Chongqing Lummy Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.43 1.55 1.60 1.60 1.55

Chongqing Lummy Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.59 1.57 1.57 1.55 1.55

Competitive Comparison of Chongqing Lummy Pharmaceutical's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, Chongqing Lummy Pharmaceutical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chongqing Lummy Pharmaceutical's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chongqing Lummy Pharmaceutical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Chongqing Lummy Pharmaceutical's Cyclically Adjusted PS Ratio falls into.



Chongqing Lummy Pharmaceutical Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Chongqing Lummy Pharmaceutical's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.17/115.2271*115.2271
=0.170

Current CPI (Mar. 2024) = 115.2271.

Chongqing Lummy Pharmaceutical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.264 98.200 0.310
201409 0.326 98.900 0.380
201412 0.470 99.000 0.547
201503 0.348 99.900 0.401
201506 0.134 99.500 0.155
201509 0.337 100.500 0.386
201512 0.491 100.600 0.562
201603 0.308 102.200 0.347
201606 0.246 101.400 0.280
201609 0.296 102.400 0.333
201612 0.454 102.600 0.510
201703 0.303 103.200 0.338
201706 0.308 103.100 0.344
201709 0.412 104.100 0.456
201712 0.500 104.500 0.551
201803 0.402 105.300 0.440
201806 0.446 104.900 0.490
201809 0.457 106.600 0.494
201812 0.620 106.500 0.671
201903 0.385 107.700 0.412
201906 0.594 107.700 0.636
201909 0.620 109.800 0.651
201912 0.690 111.200 0.715
202003 0.306 112.300 0.314
202006 0.433 110.400 0.452
202009 0.580 111.700 0.598
202012 0.560 111.500 0.579
202103 0.404 112.662 0.413
202106 0.258 111.769 0.266
202109 0.265 112.215 0.272
202112 0.315 113.108 0.321
202203 0.188 114.335 0.189
202206 0.197 114.558 0.198
202209 0.250 115.339 0.250
202212 0.203 115.116 0.203
202303 0.212 115.116 0.212
202306 0.218 114.558 0.219
202309 0.180 115.339 0.180
202312 0.243 114.781 0.244
202403 0.170 115.227 0.170

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Chongqing Lummy Pharmaceutical  (SZSE:300006) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Chongqing Lummy Pharmaceutical's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2.50/1.55
=1.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Chongqing Lummy Pharmaceutical was 7.22. The lowest was 1.54. And the median was 3.54.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Chongqing Lummy Pharmaceutical Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Chongqing Lummy Pharmaceutical's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Chongqing Lummy Pharmaceutical (SZSE:300006) Business Description

Traded in Other Exchanges
N/A
Address
99 Yuma Road, Nan'an District, chongqing, CHN, 401123
Chongqing Lummy Pharmaceutical is a wholly-owned subsidiary of Lai America Pharmaceutical Co., Ltd. and is a professional pharmaceutical sales company in China.
Executives
Yuan Yuan Supervisors
Qiu Yu Directors, executives
Leng Xue Feng Secretary, Director
Zhang Xiao Xue Supervisors
Wang Ying Director
Zhou Xue Mei Supervisors
Zhao Bin Executives
Tang Xiao Hai Executives
Fu Rong Executives
Li Xian Feng Supervisors
Qiu Wei Director

Chongqing Lummy Pharmaceutical (SZSE:300006) Headlines

No Headlines